As previously reported, Wolfe Research analyst Alexandria Hammond upgraded Merck (MRK) to Outperform from Peer Perform with a $135 price target After modeling in Merck’s late-stage pipeline assets, accounting for label expansion opportunities, and factoring in prescriber feedback, the firm view the five-year revenue bridge as “attractive” and would argue the stock is “poised for a breakout” following accretive M&A and ahead of an attractive catalyst path.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck upgraded to Outperform from Peer Perform at Wolfe Research
- LLY, JNJ, PFE: Big Pharma’s 2025 Comeback Is Bigger Than the Obesity Craze
- Merck price target raised to $130 from $105 at UBS
- Merck to complete acquisition of Cidara Therapeutics
- Merck initiates Phase 3 KANDLELIT-007 trial evaluating calderasib